Demır Ahmet Suat, Erdenen Füsun, Müderrısoğlu Cüneyt, Toros Ahmet Burak, Bektaş Hasan, Gelışgen Remise, Tabak Ömür, Altunoğlu Esma, Uzun Hafize, Erdem Huq Gülben Erdem, Aral Hale
Departments of Internal Medicine, İstanbul Training and Research Hospital, İstanbul.
Turk J Gastroenterol. 2013;24(1):36-42.
BACKGROUND/AIMS: Screening for precancerous lesions is important for the diagnosis and treatment of colorectal tumors. We investigated M2-pyruvate kinase levels in patients with colorectal polyps and carcinoma and assessed factors affecting M2-pyruvate kinase levels.
Eighty-five patients who had undergone colonoscopic examination and who were diagnosed with a neoplastic lesion were included. Patients were divided into two groups according to the macroscopic diagnosis of polyp or carcinoma. According to histopathological evaluation, specimens were grouped as nonneoplastic lesions, tubular adenoma, tubulovillous adenoma and adenocarcinoma. M2-pyruvate kinase levels were measured with the Tumor M2-pyruvate kinase ELISA kit.
Mean M2-pyruvate kinase levels were 76.1±57.73 (13.1-288.22) IU/ml. We did not find a correlation between M2-pyruvate kinase levels and age, gender, smoking, alcohol and aspirin consumption and colorectal cancer family history. There was a relationship between body mass index and M2-pyruvate kinase level (p=0.022). The carcinoma group had the highest levels of M2-pyruvate kinase both endoscopically and histopathologically (p=0.009, p=0.019 respectively). M2-pyruvate kinase levels of patients who died were significantly higher than patients who survived (p=0.001). Enzyme values were significantly lower in diabetic patients than nondiabetics (p=0.04); and chronic renal failure patients had higher levels (p=0.045).
Serum M2-pyruvate kinase levels may be useful in distinguishing malignant and benign lesions of the colon and may provide insight in terms of survival.
背景/目的：癌前病变的筛查对于结直肠肿瘤的诊断和治疗至关重要。我们研究了结直肠息肉和癌患者的M2-丙酮酸激酶水平，并评估了影响M2-丙酮酸激酶水平的因素。
纳入85例接受结肠镜检查并被诊断为肿瘤性病变的患者。根据息肉或癌的宏观诊断将患者分为两组。根据组织病理学评估，标本分为非肿瘤性病变、管状腺瘤、管状绒毛状腺瘤和腺癌。使用肿瘤M2-丙酮酸激酶ELISA试剂盒测量M2-丙酮酸激酶水平。
M2-丙酮酸激酶平均水平为76.1±57.73（13.1 - 288.22）IU/ml。我们未发现M2-丙酮酸激酶水平与年龄、性别、吸烟、饮酒、阿司匹林摄入及结直肠癌家族史之间存在相关性。体重指数与M2-丙酮酸激酶水平之间存在关联（p = 0.022）。在内镜检查和组织病理学检查中，癌组的M2-丙酮酸激酶水平均最高（分别为p = 0.009，p = 0.019）。死亡患者的M2-丙酮酸激酶水平显著高于存活患者（p = 0.001）。糖尿病患者的酶值显著低于非糖尿病患者（p = 0.04）；慢性肾功能衰竭患者的酶值较高（p = 0.045）。
血清M2-丙酮酸激酶水平可能有助于区分结肠的恶性和良性病变，并可能提供有关生存情况的见解。
